Literature DB >> 27038846

Sinusoidal obstruction syndrome.

Dominique-Charles Valla1, Dominique Cazals-Hatem2.   

Abstract

Sinusoidal obstruction syndrome (SOS) is characterized by damage to small hepatic vessels affecting particularly sinusoidal endothelium. Damaged sinusoids can be associated with a partial or complete occlusion of small hepatic veins, hence the previous denomination of hepatic veno-occlusive disease (VOD). Exposure to certain exogenous toxins appears to be specific to this condition and is frequently included in its definition. Typical histopathological features of SOS in a liver biopsy specimen are presented in the text. The purpose of this article is to provide an overview on the different entities corresponding to this general definition. Such entities include: (i) liver disease related to pyrrolizidine alcaloids; (ii) liver injury related to conditioning for hematopoietic stem cell transplantation; (iii) vascular liver disease occurring in patients treated with chemotherapy for liver metastasis of colorectal cancer; and (iv) other liver diseases related to toxic agents.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27038846     DOI: 10.1016/j.clinre.2016.01.006

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  30 in total

Review 1.  A Critical Analysis of Experimental Animal Models of Sinusoidal Obstruction Syndrome.

Authors:  Arvind Kumar; Richard Palek; Vaclav Liska
Journal:  J Clin Exp Hepatol       Date:  2018-07-17

2.  Impact of Bevacizumab on Liver Damage After Massive Hepatectomy in Rats.

Authors:  Hiroki Mori; Y U Saito; Shuichi Iwahashi; Tetsuya Ikemoto; Satoru Imura; Yuji Morine; Mitsuo Shimada
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

Review 3.  Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts.

Authors:  Dominique-Charles Valla; Dominique Cazals-Hatem
Journal:  Virchows Arch       Date:  2018-03-24       Impact factor: 4.064

Review 4.  FDA-Approved Oligonucleotide Therapies in 2017.

Authors:  Cy A Stein; Daniela Castanotto
Journal:  Mol Ther       Date:  2017-03-31       Impact factor: 11.454

5.  Oxaliplatin-induced hepatic sinusoidal obstruction syndrome in a patient with gastric cancer: A case report.

Authors:  Fang Liu; Xin Cao; Jin Ye; Xiaoli Pan; Xuefeng Kan; Yuhu Song
Journal:  Mol Clin Oncol       Date:  2017-12-18

6.  Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome.

Authors:  Vaibhav Agrawal; Praveen Ranganath; Kirsten D Ervin; Caitlin A Schmidt; Elizabeth A Cox; Robert P Nelson; Jennifer E Schwartz; Mohammad Abu Zaid; Rafat Abonour; Michael J Robertson; Bryan J Brinda; Shawn P Griffin; Teresa C Thakrar; Sherif S Farag
Journal:  Bone Marrow Transplant       Date:  2020-07-04       Impact factor: 5.483

7.  Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient.

Authors:  Richa Jain; Kirti Gupta; Anmol Bhatia; Arun Bansal; Deepak Bansal
Journal:  Indian Pediatr       Date:  2017-09-15       Impact factor: 1.411

Review 8.  Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data.

Authors:  Michel Kmeid; Xiuli Liu; Samuel Ballentine; Hwajeong Lee
Journal:  Gastroenterology Res       Date:  2021-04-21

Review 9.  Genetic Predictors for Sinusoidal Obstruction Syndrome-A Systematic Review.

Authors:  Nicolas Waespe; Sven Strebel; Simona Jurkovic Mlakar; Maja Krajinovic; Claudia Elisabeth Kuehni; Tiago Nava; Marc Ansari
Journal:  J Pers Med       Date:  2021-04-26

10.  Macrophages contribute to liver repair after monocrotaline-induced liver injury via SDF-1/CXCR4.

Authors:  Fumisato Otaka; Yoshiya Ito; Shuji Nakamoto; Nobuyuki Nishizawa; Tetsuya Hyodo; Kanako Hosono; Masataka Majima; Wasaburo Koizumi; Hideki Amano
Journal:  Exp Ther Med       Date:  2021-04-22       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.